Trade Mark Journal No.2026/018 1 May 2026

WO0000001912718 (5)

Office of origin: United States of America

Date of International Registration:16 March 2026
Date of designation in the UK: 16 March 2026
Image for mark 1912718 EMLUNZO

International priority date claimed: 26 November 2025 (United States of America) (99518790)
Class 5
Pharmaceutical preparations for the treatment of allergies and allergic diseases and disorders, autoimmune diseases and disorders, dermatological diseases and disorders, damaged skin and tissues, gastrointestinal diseases and disorders, inflammation and inflammatory diseases and disorders, respiratory diseases and disorders.

Connect Biopharma Holdings Limited

Representative: Jessica L. Rothstein Goodwin Procter LLP, 620 Eighth Avenue, New York NY 10018, UNITED STATES OF AMERICA